Recombinant Human Fibroblast Growth Factor 23 Protein (FGF23), Active

Name: Recombinant Human Fibroblast Growth Factor 23 Protein (FGF23), Active
Brand: Beta LifeScience
SKU: BLC-05981P
Availability: InStock

Collections: Cytokines, Cytokines and growth factors, Enzymes, Featured enzyme molecules, Growth factors and receptors, Kinase, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Fibroblast Growth Factor 23 Protein (FGF23), Active is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than 0.5 μg/ml, corresponding to a specific activity of >2.0x10 3 IU/mg in the presence of 0.3 ug/ml of rMuKlotho and 10 μg/ml of heparin.
Uniprotkb	Q9GZV9
Target Symbol	FGF23
Synonyms	ADHR ; FGF-23; Fgf23; FGF23_HUMAN; FGFN; Fibroblast growth factor 23 ; Fibroblast growth factor 23 C-terminal peptide; Fibroblast growth factor 23 precursor ; HPDR2 ; HYPF ; Phosphatonin; PHPTC ; Tumor derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	YPNASPLLGS SWGGLIHLYT ATARNSYHLQ IHKNGHVDGA PHQTIYSALM IRSEDAGFVV ITGVMSRRYL CMDFRGNIFG SHYFDPENCR FQHQTLENGY DVYHSPQYHF LVSLGRAKRA FLPGMNPPPY SQFLSRRNEI PLIHFNTPIP RRHTRSAEDD SERDPLNVLK PRARMTPAPA SCSQELPSAE DNSPMASDPL GVVRGGRVNT HAGGTGPEGC RPFAKFI
Expression Range	25-251aa
Protein Length	Full Length of Mature Protein
Mol. Weight	25.3 kDa
Research Area	Cancer
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
Subcellular Location	Secreted. Note=Secretion is dependent on O-glycosylation.
Protein Families	Heparin-binding growth factors family
Database References	HGNC: 3680 OMIM: 193100 KEGG: hsa:8074 STRING: 9606.ENSP00000237837 UniGene: Hs.287370
Associated Diseases	Hypophosphatemic rickets, autosomal dominant (ADHR); Tumoral calcinosis, hyperphosphatemic, familial (HFTC)
Tissue Specificity	Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).

Gene Functions References

Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
The FGF23 increase related to acute kidney injury, especially in more severe stages and in patients without diuresis, is an independent risk factor for mortality. PMID: 30009421
In patients with Autosomal Dominant Polycystic Kidney Disease, as the disease stage advanced, serum FGF-23 levels increased while s-KL decreased. In ADPKD patients, the effect of serum FGF-23 on the development of AS and atherosclerosis in peripheral vessels is independent of s-KL. PMID: 30064143
In summary, our results suggest that FGF23 gene polymorphisms are associated with the risk of developing EH in Chinese Han population. PMID: 29336609
Although there are many studies suggesting the correlation between FGF23 and Insulin resistance (IR) in different populations, this study did not find any statistically significant relationship between IR and FGF23 levels in metabolic syndrome. PMID: 30001211
Data suggest that intact FGF23 level in plasma is independent predictor of cardiovascular death in patients with heart failure and provides added value to standard of care, natriuretic peptide (NT-proBNP) plasma level, for risk estimation. This study was conducted in Belgium. (FGF23 = fibroblast growth factor 23; NT-proBNP = aminoterminal pro-B-type natriuretic peptide) PMID: 30205090
In patients with heart failure, higher plasma FGF23 levels were associated with volume overload and increased risk of all-cause mortality and hospitalization. PMID: 29306478
serum level of FGF-23 was not correlated with a change in bone mineral density of maintenance hemodialysis patients, whereas the serum Klotho protein level was associated with the degree of bone mineral density PMID: 29665846
Increased insulin resistance in chronic kidney disease is a consequence of the uremic status and is intimately associated with disturbed phosphate metabolism and FGF23. PMID: 29619868
Increased serum levels of FGF23 were associated with loss of graft function in kidney transplant recipients. PMID: 29528011
Responses of FGF23 to salt intervention were more prominent in normotensive, older than 60 years, BMI <24 kg/m(2) and salt-resistant individuals. Furthermore, a significant inverse correlation was observed between 24-hour urinary sodium and serum concentrations of FGF23 after adjusting age, sex, BMI and hypertension status. PMID: 29608553
FGF23 is reduced in subjects with nephrotic syndrome compared to healthy controls. Reduced levels of Vitamin D, and urinary losses may contribute to lower levels of FGF23 in NS. PMID: 28087977
Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH. PMID: 29457024
Carboxy-terminal fragment of FGF-23 induces heart hypertrophy in sickle cell disease. PMID: 27789679
prolonged exposure to high apical calcium and calcium hyperabsorption were sensed by CaSR, which, in turn, increased FGF-23 expression to suppress calcium transport PMID: 29317227
In a Canadian Asian population with CKD, FGF23 levels obtained at 6-monthly intervals for 3 years predicted ESRD and mortality suggesting that it is also a risk marker in Asians PMID: 28743129
shed alpha-klotho functions as an on-demand non-enzymatic scaffold protein that promotes FGF23 signalling PMID: 29342138
Long-term supplementation with modest quantities of omega-3 fatty acids does not reduce plasma FGF23 levels when added to cardiovascular medication in post-myocardial patients with chronic kidney disease. PMID: 29137111
A decrease in serum FGF23 and hepcidin levels was observed in chronic hemodialysis patients treated with lanthanum carbonate. PMID: 27928636
serum FGF23 levels were significantly higher and soluble Klotho levels significantly lower in the autosomal-dominant polycystic kidney disease group than in the non-diabetic chronic kidney disease group matched for estimated glomerular filtration rate PMID: 27450645
Higher serum fibroblast growth factor 23 concentration was associated with kidney function decline, height-adjusted total kidney volume percentage increase, and death in patients with autosomal dominant polycystic kidney disease. PMID: 28705885
This study indicates a possible mechanism by which excessive levels of FGF23 are involved in endothelial thrombomodulin disruption, which has been implicated as a potential cardiovascular risk factor in patients with chronic kidney disease, especially in hemodialysis patients PMID: 28834363
Novel relationships were identified between higher plasma FGF23 concentrations and absence of APOL1 renal-risk genotypes with higher mortality in African Americans with diabetes. PMID: 29113983
FGF23 is an integral part of a complex pathway, associated with higher cardiac mass in African-Americans males with excess adiposity. PMID: 28456498
found no independent association between FGF-23 and cardiac changes. LVH remains the most common cardiac change seen in children with CKD PMID: 28402974
Fibroblast Growth Factor-23 was higher in alcoholics than in controls, especially among cirrhotics, and soluble alpha Klotho levels were also higher among cirrhotics. PMID: 28651327
Dietary factors other than phosphate are associated with FGF23 levels in young adults. PMID: 27942978
Novel CLCN5 (c.1205G>A, p.W402*) and FGF23 (c.526C>G, p.R176G) mutations were found in two patients from the remaining two families PMID: 28383812
Review/Meta-analysis: individuals with increased plasma FGF23 levels might suffer a higher risk of all-cause mortality and cardiovascular mortality. PMID: 28411494
review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD. PMID: 28535521
In Chinese patients with type 2 diabetes, serum FGF23 levels were independently and positively correlated with the presence of lower extremity atherosclerotic disease. PMID: 28619026
studied biomarkers do not predict arrhythmia recurrence after catheter ablation. Left atrial voltage is an independent predictor of recurrence, whether the left atrium is mapped in atrial fibrillation or sinus rhythm PMID: 29293545
A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and urinary albumin creatinine ratio (r=0.768; p=0.001). PMID: 27323770
There may be positive dose-response predictive effects of FGF23 on all-cause mortality, cardiovascular disease, and renal events in patients with chronic kidney disease.[meta-analysis] PMID: 28006765
Circulating FGF23 and inflammatory cytokines are correlated with varying levels of chronic kidney disease. PMID: 27836924
study indicated that serum FGF-23 level could be served as the utility in the early detection of women with low bone mass. PMID: 28464278
Newly diagnosed Lupus nephritis (LN) patients demonstrated elevated FGF23 levels that were positively correlated to urinary MCP1, independently of vitamin D levels and kidney function. If FGF23 may predict clinical outcomes in LN warrants further evaluation. PMID: 28063327
there is a strong relationship between iron and FGF23 physiology; C-terminal FGF23 may have a role in mortality in kidney transplant recipients PMID: 28774998
FGF23 counteracts osteogenic conversion of vascular smooth muscle cells as a part of a compensatory mechanism to mitigate vascular calcification PMID: 27599364
intact FGF23 from loss of function mutants bypasses the endoplasmic reticulum/Golgi quality control system to the circulation of hyperphosphatemic familial tumoral calcinosis patients by an unknown pathway. PMID: 26620085
AN69ST-continuous hemodiafiltration can be a novel FGF-23 lowering therapy for acute illnesses requiring acute blood purification. PMID: 28164555
FGF23 and its co-receptor klotho play an important role in bone mineral and vitamin D metabolism. In chronic kidney disease, disturbances in bone metabolism increase cardiovascular risk. FGF23 levels are very high in chronic kidney disease and may contribute to vascular calcification and other cardiovascular problems. Review. PMID: 27118192
can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
Elevated levels of interleukin-6, C-reactive protein, and FGF23 are independent risk factors for mortality in chronic kidney disease. PMID: 28017325
Main demonstrable effect of FGF23 in the setting of preserved renal function is suppression of 1,25-dihydroxyvitamin D3 rather than stimulation of renal phosphate excretion. PMID: 27370409
An overview of FGF23 biology and physiology is provided, clinical outcomes that have been associated with FGF23 are summarized, potential mechanisms for these observations are discussed. PMID: 28715994
Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR. Its involvement with other hormones of mineral homeostasis (FGF23/Klotho and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney PMID: 28558021
High serum FGF23 expression is associated with acute decompensated heart failure. PMID: 26666498
High FGF-23 expression is associated with cardiovascular disease. PMID: 26888181
high i-FGF23 levels may be associated with prolongation of low levels of ferritin, resulting in increased usages of iron supplementation in HD patients PMID: 28475601

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.